EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influenza A and B Viral Shedding in Adults Immunized With Live Attenuated Influenza Vaccine

Brandon M Tower iD, Cindy M Liu iD, David J Diemert iD, Sydney G Nelson, Chelsea E Ware iD, Juan E Salazar, Tony Pham, Reed M Leventis, Katherine E Rose iD, Annie L S Roberts iD, Nathan O Weber, Edward H Sung und 3 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Brandon M Tower und 14 weiteren Autor:innen. Beteiligte Einrichtung: Antibiotic Resistance Action Center, Department of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington…. Hauptthemen laut MEDLINE: Virus Shedding, Influenza Vaccines, Influenza B virus, Influenza, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Milken Institute School of Public Health, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Live attenuated influenza vaccine (LAIV) induces mucosal immunity through limited viral replication in the upper respiratory tract, but postvaccination viral shedding dynamics and their clinical correlates remain incompletely characterized.

Methods

We evaluated 283 healthy adults (108 in 2023–2024, 175 during the 2024–2025 influenza seasons) following intranasal LAIV administration. Nasal swabs were collected on post-LAIV days 1, 2–4, and 5–7 to quantify influenza A and B RNA by RT-PCR. Viral detection, shedding duration and burden, clearance kinetics, and probability of detection were compared across seasons, vaccine strain compositions (quadrivalent vs trivalent), and host factors. Respiratory symptoms were assessed.

Results

Early viral shedding was frequent: influenza A or B RNA was detected in 86.9% of participants on day 1, with codetection in 52.7%. Probability of detection declined from 92% on day 1% to 9% on day 7. Influenza B had longer shedding duration (median, 2.0 vs 1.0 days; P < .001) and higher shedding burden (4.2 vs 4.0 log10 RNA copies/mL; P < .001). Three clearance profiles—rapid (clearance ≤4 days), moderate (5–7 days), and slow (≥7 days)—were identified. Profiles were consistent across seasons but influenza B was disproportionately represented in slower-clearance groups (P < .001). Total viral burden (P < .01) and shedding duration (P = .01) were associated with total symptom burden.

Conclusions

LAIV replication begins within 24 h and declines over the first week, with persistent shedding uncommon after day 7. Influenza B replicates more extensively and persists longer than influenza A. Symptom burden correlates with shedding duration and viral burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus SheddingInfluenza VaccinesInfluenza B virusInfluenza, HumanInfluenza A virusHumansVaccines, AttenuatedFemaleMaleAdultMiddle AgedRNA, ViralYoung AdultAdministration, IntranasalAdolescentViral Load

Stichwörter der Autor:innen

immunizationinfluenzalive attenuated influenza vaccineviral shedding

Substanzen

Influenza VaccinesVaccines, AttenuatedRNA, Viral

Autor:innen und Institutionen

  • Antibiotic Resistance Action Center, Department of Environmental and Occupational Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
  • George Washington University School of Medicine and Health Sciences, Department of Microbiology, Tropical Medicine and Immunology, Washington, DC, USA.
  • George Washington Vaccine Research Unit, George Washington Medical Faculty Associates, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
  • Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

ORCID-Profile: Brandon M Tower, Cindy M Liu, David J Diemert, Chelsea E Ware, Katherine E Rose, Annie L S Roberts, Maliha Aziz, Ryan M Troyer, Daniel E Park

Förderung

  • NIAID NIH HHS
  • Milken Institute School of Public Health
  • NIH HHS
  • George Washington University
  • National Institutes of Health

Zitieren

APA

Tower, B. M., Liu, C. M., Diemert, D. J., Nelson, S. G., Ware, C. E., Salazar, J. E., Pham, T., Leventis, R. M., Rose, K. E., Roberts, A. L. S., Weber, N. O., Sung, E. H., Aziz, M., Troyer, R. M., & Park, D. E. (2026). Influenza A and B Viral Shedding in Adults Immunized With Live Attenuated Influenza Vaccine. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag294

Vancouver

Tower BM, Liu CM, Diemert DJ, Nelson SG, Ware CE, Salazar JE, et al. Influenza A and B Viral Shedding in Adults Immunized With Live Attenuated Influenza Vaccine. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag294

BibTeX
@article{Tower2026,
  author = {Tower, Brandon M and Liu, Cindy M and Diemert, David J and Nelson, Sydney G and Ware, Chelsea E and Salazar, Juan E and Pham, Tony and Leventis, Reed M and Rose, Katherine E and Roberts, Annie L S and Weber, Nathan O and Sung, Edward H and Aziz, Maliha and Troyer, Ryan M and Park, Daniel E},
  title = {Influenza A and B Viral Shedding in Adults Immunized With Live Attenuated Influenza Vaccine},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag294}
}
Kostenlos starten →